Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash & Equivalents (2016 - 2025)

Cytosorbents (CTSO) has disclosed Cash & Equivalents for 14 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 15.94% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Sep 2025, up 15.94%, and an annual FY2024 reading of $3.3 million, down 76.79% over the prior year.
  • Cash & Equivalents was $7.5 million for Q3 2025 at Cytosorbents, down from $10.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $68.5 million in Q1 2021 and bottomed at $3.3 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $24.9 million, with a median of $14.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 159.46% in 2021, then tumbled 76.79% in 2024.
  • Year by year, Cash & Equivalents stood at $52.1 million in 2021, then tumbled by 57.53% to $22.1 million in 2022, then crashed by 36.19% to $14.1 million in 2023, then crashed by 76.79% to $3.3 million in 2024, then soared by 129.76% to $7.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for CTSO at $7.5 million in Q3 2025, $10.2 million in Q2 2025, and $11.6 million in Q1 2025.